icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Paris France
11-15 April 2018
Back grey_arrow_rt.gif
 
 
 
FIRST REAL-WORLD DATA ON SAFETY AND EFFECTIVENESS OF GLECAPREVIR/PIBRENTASVIR FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION: DATA FROM THE GERMAN HEPATITIS C-REGISTRY
 
 
  Reported by Jules Levin
EASL - 53rd Annual Meeting of the European Association for the Study of the Liver Paris, France
13 April 2018
 
Thomas Berg1, Uwe Naumann4, Albrecht Stoehr5, Christoph Sick6, Gerlinde Teuber7, Willibold Schiffelholz8, Stefan Mauss9, Jan Hettinger3, Henning Kleine3, Andreas Pangerl3, Claus Niederau2
 
1Section of Hepatology, Clinic of Gastroenterology and Rheumatology, University Hospital Leipzig, Leipzig, Germany; 2. Katholisches Klinikum Oberhausen, St. Josef-Hospital, Klinik fur Innere Medizin,
Akademisches Lehrkrankenhaus der Universitšt Duisburg-Essen, Oberhausen, Germany; 3. AbbVie Inc., North Chicago, Illinois, U.S.A; 4. UBN-Praxis , Berlin, Germany; 5. IFI Studien und Projekte GmbH, Hamburg, Germany; 6. Praxisonkologie Bremen, Bremen, Germany; 7. Practice PD Dr. med. G. Teuber, Frankfurt am Main, Germany; 8. Gastroenterologische Schwerpunktpraxis, Augsburg, Germany; 9. Center for HIV and Hepatogastroenterology, Dusseldorf, Germany

0413181

0413182

0413183

0413184

0413185

0413186

0413187

0413188